EMA Authorised: Anzupgo (Delgocitinib) — LEO Pharma A/S

View source ↗

Summary

Anzupgo (delgocitinib) has been authorised by the EMA for dermatitis/eczema with LEO Pharma A/S as the marketing authorization holder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis
• Dermatitis

Drugs mentioned

• ANZUPGO (delgocitinib)

Snippet

Status: Authorised. Therapeutic area: Dermatitis;Eczema. MAH: LEO Pharma A/S. Decision date: 23/10/2025